Lsv Asset Management Biogen Inc. Transaction History

Lsv Asset Management

$46.7 Billion
Q3 2024

A detailed history of Lsv Asset Management transactions in Biogen Inc. stock. As of the latest transaction made, Lsv Asset Management holds 41,500 shares of BIIB stock, worth $6.55 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

41,500

Holding current value

$6.55 Million

% of portfolio

0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$189.07 - $236.8 $7.85 Million - $9.83 Million	41,500 New	41,500 $8.04 Million
Q4 2023 Feb 06, 2024	SELL	$222.59 - $267.94 $50.7 Million - $61 Million	-227,622 Reduced 66.04%	117,030 $30.3 Million
Q3 2023 Nov 03, 2023	SELL	$253.3 - $285.89 $2.22 Million - $2.51 Million	-8,772 Reduced 2.48%	344,652 $88.6 Million
Q2 2023 Aug 02, 2023	SELL	$275.25 - $318.06 $3.59 Million - $4.14 Million	-13,030 Reduced 3.56%	353,424 $101 Million
Q1 2023 May 02, 2023	BUY	$256.56 - $292.34 $1.95 Million - $2.22 Million	7,600 Added 2.12%	366,454 $102 Million
Q4 2022 Feb 08, 2023	SELL	$252.44 - $306.72 $2.59 Million - $3.15 Million	-10,268 Reduced 2.78%	358,854 $99.4 Million
Q3 2022 Nov 07, 2022	SELL	$194.69 - $268.46 $258,937 - $357,051	-1,330 Reduced 0.36%	369,122 $98.6 Million
Q2 2022 Aug 10, 2022	SELL	$187.54 - $223.02 $599,752 - $713,217	-3,198 Reduced 0.86%	370,452 $75.6 Million
Q1 2022 May 12, 2022	BUY	$193.77 - $244.14 $3.61 Million - $4.55 Million	18,628 Added 5.25%	373,650 $78.7 Million
Q4 2021 Jan 28, 2022	SELL	$223.92 - $287.77 $1.47 Million - $1.89 Million	-6,580 Reduced 1.82%	355,022 $85.2 Million
Q3 2021 Nov 04, 2021	BUY	$282.99 - $369.05 $405,241 - $528,479	1,432 Added 0.4%	361,602 $102 Million
Q2 2021 Aug 04, 2021	SELL	$259.0 - $414.71 $145 Million - $231 Million	-557,961 Reduced 60.77%	360,170 $125 Million
Q1 2021 Apr 30, 2021	SELL	$242.95 - $284.63 $4.91 Million - $5.75 Million	-20,210 Reduced 2.15%	918,131 $257 Million
Q4 2020 Feb 08, 2021	SELL	$236.26 - $355.63 $12 Million - $18 Million	-50,751 Reduced 5.13%	938,341 $230 Million
Q3 2020 Oct 23, 2020	SELL	$264.77 - $305.71 $4.94 Million - $5.71 Million	-18,666 Reduced 1.85%	989,092 $281 Million
Q2 2020 Aug 05, 2020	SELL	$258.66 - $342.55 $17.4 Million - $23 Million	-67,119 Reduced 6.24%	1,007,758 $270 Million
Q1 2020 May 07, 2020	SELL	$268.85 - $341.04 $12.1 Million - $15.3 Million	-44,956 Reduced 4.01%	1,074,877 $340 Million
Q4 2019 Feb 10, 2020	BUY	$220.06 - $304.07 $411,292 - $568,306	1,869 Added 0.17%	1,119,833 $332 Million
Q3 2019 Nov 07, 2019	BUY	$217.44 - $243.88 $10.9 Million - $12.2 Million	50,220 Added 4.7%	1,117,964 $260 Million
Q2 2019 Aug 08, 2019	BUY	$219.29 - $241.72 $31.8 Million - $35 Million	144,830 Added 15.69%	1,067,744 $250 Million
Q1 2019 May 07, 2019	BUY	$216.71 - $338.96 $30.9 Million - $48.3 Million	142,412 Added 18.25%	922,914 $218 Million
Q4 2018 Feb 05, 2019	BUY	$278.5 - $352.75 $5.96 Million - $7.55 Million	21,391 Added 2.82%	780,502 $235 Million
Q3 2018 Nov 06, 2018	BUY	$293.51 - $383.83 $49.4 Million - $64.6 Million	168,183 Added 28.46%	759,111 $268 Million
Q2 2018 Aug 08, 2018	BUY	$257.52 - $306.91 $7.28 Million - $8.68 Million	28,269 Added 5.02%	590,928 $172 Million
Q1 2018 May 04, 2018	BUY	$260.13 - $367.91 $18 Million - $25.5 Million	69,220 Added 14.03%	562,659 $154 Million
Q4 2017 Feb 01, 2018	BUY	$307.64 - $344.58 $2.37 Million - $2.65 Million	7,705 Added 1.59%	493,439 $0
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $137 Million - $160 Million	485,734	485,734 $152 Million

Others Institutions Holding BIIB

# of Institutions

1,036

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lsv Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Lsv Asset Management with notifications on news.

Account

Lsv Asset Management Biogen Inc. Transaction History